Summary of Key Points
Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), which accounts for 95% of cases, is often referred to as the "king of cancers" due to its asymptomatic nature in the early stages and limited treatment options. Recently, a new generation of RAS-targeted drug, daraxonrasib, has made breakthrough progress in phase III clinical trials: it increased the median survival period for patients receiving second-line treatment from 6.7 months with chemotherapy to 13.2 months, reducing the risk of death by 60%, and holds promise for a new era in pancreatic cancer therapy. Additionally, mRNA vaccines and AI-based early screening technologies have also brought new hope for treatment. Prevention, however, still relies on maintaining healthy lifestyle habits.
Detailed Explanation
#### Why is Pancreatic Cancer the "King of Cancers"?
The severity of pancreatic cancer stems from three main factors:
- Difficult to detect in the early stages: The pancreas is located deep within the abdomen, and there are almost no symptoms in the early stages. By the time symptoms such as abdominal pain and jaundice appear, 80% of patients have already progressed to local or advanced stages, making it impossible to completely remove the tumor through surgery (such as the Whipple procedure).
- The most lethal type accounts for a high proportion: 95% of pancreatic cancers originate from the exocrine part of the pancreas, and 85% of these are PDACs. PDACs progress rapidly, with very low survival rates—patients in the late stages have a median survival of only about one year even after chemotherapy.
- Limited treatment options: Chemotherapy is not effective against pancreatic cancer, and no breakthroughs have been made with targeted drugs (the reasons for this will be discussed later). Even Steve Jobs did not die from PDAC; he had a neuroendocrine tumor of the pancreas, which has a relatively better prognosis. However, his death was due to his rejection of conventional treatments, highlighting the severity of PDAC.
#### Why Have Previous Targeted Drugs Been Ineffective Against Pancreatic Cancer?
Cancer cells grow rapidly due to genetic mutations, and targeted drugs aim to target these specific mutations. The core mutation in pancreatic cancer is the RAS protein mutation, which has proven to be a challenging target:
- High prevalence of RAS mutations: 85-90% of pancreatic cancers have RAS mutations (especially KRAS), but the structure of the RAS protein makes it difficult for drugs to bind to, leading it to be classified as an "undruggable" target.
- Early-stage targeted drugs were ineffective: Scientists later identified a target for the G12C mutation in KRAS (a change in the 12th amino acid) and developed sotorasib (approved in 2021), but this mutation only occurs in 1% of pancreatic cancer cases, making it almost useless. Moreover, long-term use of sotorasib can cause the RAS protein to switch from an inactive to an active state, quickly leading to drug resistance.
#### What Makes the New Generation of Targeted Drug Daraxonrasib So Promising?
Daraxonrasib, which received a standing ovation at the ASCO conference, addresses the two major issues with previous targeted drugs:
- Smarter mechanism: It first binds to a cellular protein called cyclophilin A and uses this protein to deliver the drug directly to the active form of RAS. This approach inhibits RAS regardless of whether the mutation is G12D, G12V, or other types.
- Unprecedented clinical results: In second-line treatment (after first-line chemotherapy failed), the median survival period nearly doubled from 6.7 months to 13.2 months, with a 60% reduction in the risk of death. This is a breakthrough in pancreatic cancer therapy and is likely to be approved by the FDA soon.
#### Other Promising Developments:
- mRNA Vaccines: Early trials have shown that in 16 patients, 8 had their anti-tumor immune cells activated, and 7 have survived for more than six years, suggesting the potential to turn advanced pancreatic cancer into a chronic disease.
- AI-based early screening: AI can detect pancreatic cancer more accurately through medical imaging. AI models developed in China, for example, have shown promise in this area, with higher surgical cure rates for patients detected at an early stage.
#### What Can Ordinary People Do?
Pancreatic cancer primarily affects people over the age of 40, and risk factors include diabetes, chronic pancreatitis, smoking, excessive drinking, and obesity. Here are some steps ordinary people can take:
- Quit smoking and limit alcohol consumption.
- Maintain a healthy weight and avoid overeating.
- Have regular check-ups, especially if you have diabetes or chronic pancreatitis.
- Seek medical attention early—early-stage pancreatic cancer often has no noticeable symptoms, so prevention is more important than treatment.
Final Reminder
Despite these advancements, pancreatic cancer remains a serious disease, with late-stage patients still facing a survival period of only months. However, the progress of new drugs means that the "king of cancers" is no longer an insurmountable challenge. As more technologies mature, the lethality of pancreatic cancer will gradually decrease. For everyone, maintaining a healthy lifestyle is the best form of prevention.